The Venture Codex Logo

The Venture Codex

Skolkovo Foundation

Skolkovo Innovation Center, Lugovaya St., 4, Moscow, Moscow City, 143026, Russian Federation

Overview

Skolkovo Foundation is a Russian organization that fosters startups and venture capitals focused on the areas of energy, IT, biomedicine, nuclear, and space. The IT cluster develops strategic directions of information technologies, including search systems and cloud calculations. The biomed cluster supports and develops innovations in the field of biomedical technologies. The energy Efficiency cluster supports innovations and advanced technologies, aimed at the reduction of energy consumption by industrial and residential objects as well as lower energy consumption by communal services and municipal infrastructure facilities. The space technologies cluster handles space projects and the development of telecommunication technologies based on space tourism, satellite navigation systems, and more. The nuclear technology cluster supports the creation of new products for power markets, development of new materials, and designing of complex technological systems. In order to carry out its operations, Skolkovo Foundation manages Skolkovo Innovation Center, Technopark, Skolkovo Institute of Technology (Skoltech), and Skolkovo city. Several companies, including Boeing, Cisco Systems, EADS, GE, Johnson & Johnson, IBM, Intel, Microsoft, Siemens, Nokia, and Samsung have signed R&D partnership agreements with Skolkovo Foundation. Skolkovo Foundation was founded in September 2010 and is based in Moscow, Russia.

Total investments
1
Lead investments
1
Investments · 12mo
0
Active investors
8

Sector focus

  • Health Care
  • Information Technology
  • Innovation Management
  • Navigation
  • Non Profit
  • Venture Capital
Visit website

Investment portfolio

  • Viriom

    Led · Grant · May 2016

    Viriom Inc. is a San Diego–based late-stage biotech developing, manufacturing and distributing novel and affordable therapies against life‑threatening infections including HIV and HBV. Its lead asset is Elpida (elpivirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV to which Viriom holds an exclusive worldwide license from F. Hoffmann‑La Roche; Elpida is in Phase 2–3. The company is also developing a proprietary treatment for chronic HBV. Viriom raised $4.7M in a financing that combined equity and non‑equity instruments. A portion of the financing is a three‑year $2.35M grant from The Skolkovo Foundation to support development of fixed‑dose combinations and long‑acting injectable formulations of Elpida. ChemRar and Torrey Pines Investment committed matching capital on a pari passu basis to support the program.

Team

  • Igor Agamirzyan

    General Director of the Russian Venture Company OJSC

  • Dmitry Kalaev

    expert of IT-cluster

    LinkedIn
  • Dmitry Pumpyanskiy

    Chairman

  • Veniamin Golubitsky

    Co-Chairman